close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.04 -0.46 (-2.49%)
Streaming Delayed Price Updated: 10:48 AM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
News headline image
Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label ↗
Analysts downgraded Sarepta as FDA pause on Elevidys raises regulatory uncertainty, leading to significant stock pressure and valuation cuts. 
Via Benzinga
Arrowhead Pharma Expects Sarepta Therapeutics To Continue Meeting Financial Obligations: Retail Cheers The Announcement ↗
Via Stocktwits
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Levi &amp; Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc. (SRPT) Shareholders
Via TheNewswire.com
Topics Fraud Lawsuit
Sarepta Pauses Shipments Of DMD Drug Elevidys Amid FDA Label Review, Stock Tumbles After-Hours ↗
Via Stocktwits
News headline image
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc. (SRPT) Shareholders
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division ↗
George Tidmarsh appointed to lead FDA drug review division amid staffing cuts and scrutiny over accelerated approvals and drug advertising rules. 
Via Benzinga
News headline image
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Sarepta Tumbles On The 'Painful' Decision To Stop Selling Elevidys ↗
Sarepta stock toppled Tuesday after the company said it would voluntarily stop all shipments of Elevidys. 
Via Investor's Business Daily
Topics Death ETFs
News headline image
Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review ↗
Sarepta pauses U.S. Elevidys shipments to complete FDA-requested safety label updates, aiming to resume distribution in the fourth quarter. 
Via Benzinga
News headline image
Agilysys Posts Downbeat Earnings, Joins NXP Semiconductors And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This Lululemon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets ↗
Sarepta faces FDA scrutiny over Elevidys as analysts downgrade stock and warn of long-term debt risks amid market uncertainty. 
Via Benzinga
News headline image
Sarepta Topples, Again, After Refusing The FDA's Request To Pull Elevidys ↗
The company is setting up for a showdown with the FDA over its approved gene therapy, Elevidys. 
Via Investor's Business Daily
Topics Death Government
News headline image
Contact Levi & Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Contact Levi &amp; Korsinsky by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. (SRPT)
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Evotec, Webull And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Monday's pre-market session. ↗
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
SAREPTA THERAPEUTICS, INC. (NASDAQ: SRPT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Sarepta Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys ↗
FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due to safety concerns. 
Via Benzinga
Topics Death
News headline image
GlucoTrack, Sarepta, TNF Pharma Dominate Weekly Retail Health Care Buzz — Here’s Why ↗
GlucoTrack repurchased over 90% of its Series A warrants, while Sarepta disclosed a third patient death, suspended Elevidys shipments, and added a black-box warning amid FDA scrutiny. 
Via Stocktwits
Topics Death Workforce
News headline image
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Sarepta Therapeutics Provides Statement on ELEVIDYS
From Sarepta Therapeutics, Inc.
Via Business Wire
News headline image
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Investors in Sarepta Therapeutics, Inc. Should Contact Levi &amp; Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT
Via TheNewswire.com
Topics Fraud Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today